CAMPBELL, Calif., June 25, 2026 – Saama, a provider of AI-based solutions that accelerates clinical development and commercialization, today announced that it is the recipient of “AI-based Life Sciences Solution of the Year” in the 9th annual AI Breakthrough Awards program conducted by AI Breakthrough, a leading market intelligence organization that recognizes the top companies, technologies and products in the global Artificial Intelligence (AI) market today.
Saama’s unified, AI-driven platform enables pharma and biotech companies to streamline clinical operations, improve data quality and access, and gain faster insights across clinical trials, accelerating the time to market for novel treatments.
Saama’s Agentic AI Framework platform deploys specialized AI agents across the clinical development lifecycle. These agents autonomously assess, execute, and report tasks based on contextual understanding, resulting in optimized operational efficiency that allows human experts to focus on high-value strategic decision-making.
Recently, the company has launched the industry’s first solution to automate ADaM package generation. The ADaM Navigator eliminates the need for a manual, step-by-step workflow to generate ADaM specs, programs, and define.xml. Together with Saama’s agentic-AI SDTM Navigator, these solutions enable statistical programmers to generate accurate, efficient, and regulatory-compliant submissions-grade deliverables at scale.
Using the SDTM Navigator and ADaM Navigator has the potential to improve productivity and efficiency of statistical programming workflows, and ADaM Navigator helps to save time and resources, so that clinical experts can handle more clinical studies. As part of Saama’s platform, the new built-in technologies enable drug developers to seamlessly integrate the innovations directly into their existing technology stack, immediately benefiting their teams and patients.
“Being recognized for the third consecutive year by the AI Breakthrough Awards reflects Saama’s continued focus on delivering responsible AI with real results,” said Bhaskar Sambasivan, CEO of Saama. “As clinical data environments become more complex, our priority is to build intelligent systems that reduce manual effort, improve accuracy, and drive measurable impact across clinical development. Our Agentic AI capabilities are helping life sciences organizations achieve greater speed, scale, and confidence in execution while staying grounded in real-world outcomes.”
For nearly a decade, the AI Breakthrough Awards have researched, analyzed, and recognized the most important advances in artificial intelligence, and this year’s field is the strongest yet. Thousands of nominations from over 20 countries poured in across categories, including Agentic AI, Generative AI, Computer Vision, AIOps, Robotics, Natural Language Processing, and industry-specific AI applications – underscoring the explosive global growth of AI and its importance as the defining technology of our time.
“The Saama platform of AI-enabled solutions supports the full spectrum of clinical development. For life sciences companies, clinical research processes are manual, slow, and resource-intensive, including increasingly complex, fragmented, and data-intensive clinical trials. Traditional approaches hinder collaboration and ultimately can delay the development of novel therapies,” said Steve Johansson, managing director, AI Breakthrough. “Saama’s next-generation automation helps to bring new treatments to patients faster. By integrating autonomous decision-making, intelligent workflow automation, and human-in-the-loop oversight, Saama’s AI enhances human expertise and brings intelligence and efficiency to clinical research. We’re awarding Saama with ‘AI-based Life Sciences Solution of the Year.’”
About Saama
Saama develops healthcare and life science products and solutions that accelerate the delivery of therapies to patients. Saama also provides specialized data, analytics, and AI services to other industries. The company’s AI-driven clinical data management platform enables pharma and biotech companies to streamline clinical and commercial operations, improve data quality and access, and gain faster insights across their clinical trials. The Saama platform powered the clinical trial that led to the world’s first COVID-19 vaccine. Headquartered in Campbell, CA, with employees around the globe, Saama is committed to helping customers save and improve lives. Discover more at saama.com.
About AI Breakthrough
Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the AI Breakthrough Awards program is devoted to honoring excellence in Artificial Intelligence technologies, services, companies, and products. The AI Breakthrough Awards provide public recognition for the achievements of AI companies and products in categories including Agentic AI, Machine Learning, Generative AI, Robotics, AI Hardware, Computer Vision, and more. For more information, visit AIBreakthroughAwards.com.
Tech Breakthrough LLC does not endorse any vendor, product or service depicted in our recognition programs, and does not advise technology users to select only those vendors with award designations. Tech Breakthrough LLC recognition consists of the opinions of the Tech Breakthrough LLC organization and should not be construed as statements of fact. Tech Breakthrough LLC disclaims all warranties, expressed or implied, with respect to this recognition program, including any warranties of merchantability or fitness for a particular purpose.
Read AI Breakthrough’s press release to learn more about this recognition
